

Table 46: COVID-19 Therapeutics (also see prescribing information and emergency use authorizations [FDA(c) 2025; FDA(b) 2024])		
→ Molnupiravir, nirmatrelvir/ritonavir (RTV), monoclonal antibodies		
Class or Drug	Mechanism of Action	Clinical Comments
<ul style="list-style-type: none"> <li>All NRTIs</li> <li>Doravirine (DOR)</li> <li>Etravirine (ETR)</li> <li>Rilpivirine (RPV)</li> <li>Cabotegravir (CAB)</li> <li>Dolutegravir (DTG)</li> <li>Raltegravir (RAL)</li> </ul>	No clinically significant interactions expected.	No dose adjustments are necessary.
<ul style="list-style-type: none"> <li>Efavirenz (EFV)</li> <li>Nevirapine (NVP)</li> <li>Bictegravir (BIC)</li> <li>Fostemsavir (FTR)</li> <li>Maraviroc (MRV)</li> </ul>	<ul style="list-style-type: none"> <li><b>Molnupiravir and monoclonal antibodies</b> do not affect CYP450, P-gP, or other drug metabolism transporters.</li> <li><b>Nirmatrelvir/RTV:</b> Inhibition of CYP3A4, P-gP, and other transporters may increase plasma concentrations of other medications.</li> </ul>	<ul style="list-style-type: none"> <li><b>Molnupiravir, monoclonal antibodies:</b> Drug interactions are unlikely.</li> <li><b>Nirmatrelvir/RTV:</b> Drug interactions are unlikely; ARV levels may increase.</li> </ul>
All PIs and boosted PIs	<ul style="list-style-type: none"> <li><b>Molnupiravir and monoclonal antibodies</b> do not affect CYP450, P-gP, or other drug metabolism transporters.</li> <li><b>Nirmatrelvir/RTV:</b> Inhibition of CYP3A4, P-gP, and other transporters may increase plasma concentrations of other PIs.</li> </ul>	<ul style="list-style-type: none"> <li><b>Molnupiravir, monoclonal antibodies:</b> Drug interactions are unlikely.</li> <li><b>Nirmatrelvir/RTV:</b> Patients on RTV- or COBI-containing regimens should continue treatment for COVID-19 and HIV as indicated without adjustment. Monitor for increased PI-related adverse effects.</li> </ul>
Elvitegravir (EVG), boosted	<ul style="list-style-type: none"> <li><b>Molnupiravir and monoclonal antibodies</b> do not affect CYP450, P-gP, or other drug metabolism transporters.</li> <li><b>Nirmatrelvir/RTV:</b> Inhibition of CYP3A4, P-gP, and other transporters may increase plasma concentrations of other medications.</li> </ul>	<ul style="list-style-type: none"> <li><b>Molnupiravir, monoclonal antibodies:</b> Drug interactions are unlikely.</li> <li><b>Nirmatrelvir/RTV:</b> Patients on RTV- or COBI-containing regimens should continue treatment as indicated. Monitor for increased EVG-related adverse effects.</li> </ul>
<b>Abbreviations:</b> ARV, antiretroviral; COBI, cobicistat; CYP, cytochrome P450; NRTI, nucleoside reverse transcriptase inhibitor; P-gP, P-glycoprotein.		

## References

FDA(b). Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules. 2024 Jun. <https://www.fda.gov/media/155054/download> [accessed 2022 Jun 30]

FDA(c). Paxlovid (nirmatrelvir tablets; ritonavir tablets), co-packaged for oral use. 2025 Feb. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/217188s010lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217188s010lbl.pdf) [accessed 2022 Jun 30]